10-Q: Neogen Q2 FY26: Revenue Declines Amid Restructuring & Legal Challenges

Neogen Corporation reported a net income of $20.4 million for the first six months of fiscal year 2026, primarily driven by a divestiture gain, despite a 3% revenue decline and ongoing operational inefficiencies.

Summary

• Total revenues decreased by $6.6 million (3%) to $224.7 million for the three months ended November 30, 2025, and by $14.3 million (3%) to $433.9 million for the six months ended November 30, 2025, compared to the prior year periods.
• Net loss for the three months ended November 30, 2025, was $15.9 million, a significant improvement from a $456.3 million net loss in the prior year, which included a $461.4 million goodwill impairment charge.
• Net income for the six months ended November 30, 2025, was $20.4 million, compared to a net loss of $468.9 million in the prior year, largely due to a $76.4 million gain on the sale of the Cleaners & Disinfectants business.
• Gross margin decreased to 47.5% for the three months and 46.5% for the six months ended November 30, 2025, from 49.0% and 48.7% respectively in the prior year, primarily due to higher manufacturing costs, tariffs, inventory write-offs, and duplicative costs.
• The company initiated a restructuring plan in the second quarter of fiscal year 2026, including a reduction of approximately 10% in global headcount and other non-labor cost reductions.
• Material weaknesses in internal control over financial reporting were identified as of May 31, 2025, and remained ineffective as of November 30, 2025, with a remediation plan underway.
• Multiple shareholder class action and derivative lawsuits have been filed, alleging false and misleading statements and breaches of fiduciary duties related to the integration of the 3M Food Safety Business.

Sentiment

Score: 4

Explanation: The company faces significant operational headwinds, including declining revenue, contracting gross margins, and persistent production inefficiencies. While net income improved due to a one-time divestiture gain and the absence of a prior-year goodwill impairment, core performance remains challenged. Ongoing material weaknesses in internal controls and multiple legal proceedings add to the negative sentiment, despite active restructuring and debt reduction efforts.

Positives

• Net income for the six months ended November 30, 2025, was $20.4 million, a significant improvement from a $468.9 million net loss in the prior year, primarily driven by a $76.4 million gain on the sale of the Cleaners & Disinfectants business.
• Operating loss significantly improved to $5.4 million for the three months and $21.5 million for the six months ended November 30, 2025, compared to large losses in the prior year that included a $461.4 million goodwill impairment.
• Net cash provided by operating activities increased by $8.0 million to $30.3 million for the six months ended November 30, 2025, driven by improvements in working capital.
• Cash provided by investing activities increased by $136.9 million to $86.1 million for the six months ended November 30, 2025, primarily due to $121.7 million in cash proceeds from the sale of the Cleaners & Disinfectants business.
• Debt was reduced by $100 million through repayments using proceeds from the Cleaners & Disinfectants divestiture, with no additional required principal payments for the Term Loan until Q2 FY27.
• Food Safety segment revenue saw $6.8 million in business growth for the three months ended November 30, 2025, led by indicator sales and improvements in sample collection.
• Animal Safety segment operating income increased by $9.2 million for the three months and $11.1 million for the six months ended November 30, 2025, due to favorable product mix, lower material costs, and restructuring actions.

Negatives

• Total revenues decreased by 3% for both the three and six months ended November 30, 2025, primarily due to divestitures and discontinued product lines, as well as declines in certain product categories like veterinary instruments and natural toxins.
• Gross margin decreased to 47.5% (three months) and 46.5% (six months) from 49.0% and 48.7% in the prior year, impacted by higher manufacturing costs for the sample collection product line, increased tariffs, inventory write-offs, and duplicative costs related to Petrifilm production.
• Operating expenses, excluding the prior year's goodwill impairment, increased due to investments in transformation initiatives, transaction costs, and restructuring costs.
• The company continues to face economic headwinds including input cost inflation, softening consumer demand, elevated interest rates, and ongoing geopolitical tensions.
• Production inefficiencies in the sample collection product line continued in the first half of fiscal year 2026, following delays in restarting full production in fiscal year 2025.
• Market share loss stemming from ERP system implementation and order fulfillment issues in fiscal year 2024 continued to impact results in fiscal year 2025.
• Elevated inventory write-offs occurred in fiscal year 2025, particularly in the fourth quarter, due to expiration from supply chain and distribution challenges.

Risks

• Continued integration challenges of the 3M food safety business and the realization of expected benefits from that acquisition.
• Performance and relationship with the transition manufacturing partner.
• Ability to adequately and timely remediate identified material weaknesses in internal control over financial reporting.
• Intense competition in the food and animal safety markets.
• Recruitment and retention of key employees.
• Impact of weather on agriculture and food production.
• Global business disruption caused by geopolitical events, such as the Russia invasion in Ukraine and related sanctions.
• Risks associated with the identification and integration of future acquisitions.
• Research and development risks, including the successful commercialization of new products.
• Intellectual property protection challenges.
• Increasing and developing government regulation.
• Input cost inflation, including increases in raw materials.
• Softening consumer demand and elevated interest rates.
• Potential for increased costs and negative sales impact from increasing tariffs and retaliatory tariffs.
• Lower levels of food production in the Food Safety industry end market.
• Weakness in the companion animal market and higher levels of customer in-sourcing impacting the genomics business.

Future Outlook

The company anticipates continued impact from economic headwinds, including softening consumer demand, elevated interest rates, and geopolitical tensions, throughout fiscal year 2026. Production inefficiencies in the sample collection product line are expected to show continued improvement for the remainder of the current fiscal year. Management is actively implementing a remediation plan to address material weaknesses in internal control over financial reporting. Capital expenditures for fiscal year 2026 are estimated at approximately $50 million, with a significant portion dedicated to the integration of acquired 3M FSD products and a new manufacturing facility.

Management Comments

• Management is optimistic about the long-term prospects of the business despite current economic headwinds.
• The company is actively evaluating the nature and extent of current issues and their impact on the business, including consolidated results of operations, financial condition, and liquidity.
• We believe that our cash flows from operations, cash on hand, and borrowing capacity will enable us to fund the operating business, repay debt obligations, construct new manufacturing facilities, commercialize products currently under development, and execute our strategic plans.
• We are optimistic about potential future revenue growth in the Animal Safety segment, particularly as a result of our commercial teams leveraging extensive and longstanding partnerships in the distribution channels.

Industry Context

The Food Safety industry end market generally continues to experience a lower level of food production, largely due to the cumulative effect of significant recent inflation, particularly in food prices, though there are signs of sequential improvement in certain key product lines. The Animal Safety end market has remained near cyclical lows. The companion animal market, a portion of the genomics business, is experiencing weakness due to continued inflation, lower pet adoptions, and increased customer in-sourcing. The company also notes the impact of increasing tariffs and elevated interest rates as broader economic challenges.

Comparison to Industry Standards

• The company's Relative Total Shareholder Return (rTSR) is measured against a peer group consisting of all companies in the S&P 600 Healthcare Equipment and Services for performance share unit awards. No specific comparative results or benchmarks against this peer group are provided in the filing.

Management Changes

Corporate Governance

Legal Proceedings

• On July 18, 2025, Operating Engineers Construction Industry and Miscellaneous Pension Fund filed a putative class action complaint alleging claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, based on allegedly false and misleading public statements and omissions during January 5, 2023, through June 3, 2025, related to the integration of the 3M business into Neogen.
• On August 27, 2025, a putative class action was filed in Minnesota's Second Judicial District for Ramsey County, asserting claims under Sections 11, 12(a)(2), and 15 of the Securities Act of 1933, based on allegedly false and misleading public statements in offering materials connected to the 2022 acquisition of 3M's Food Safety Business.
• On August 13, 2025, August 15, 2025, and December 22, 2025, the company received three separate stockholder litigation demands requesting the Board investigate the allegations in the Federal Action and pursue claims on the company's behalf.
• On December 4, 2025, a putative shareholder derivative action was filed, asserting claims under Section 14 of the Securities Exchange Act of 1934 and Michigan corporate law, based on allegedly false and misleading public statements and alleged breaches of fiduciary duties related to the integration of the 3M business into Neogen.
• The company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility, with an accrued liability of $916,000 as of November 30, 2025, measured over an estimated period of 15 years. A change in remediation strategy could increase future costs.

Stakeholder Impact

• Shareholders: Potential negative impact from ongoing litigation, operational challenges, and internal control weaknesses, which could affect share price and investor confidence. Equity value could be diluted if future capital raises involve issuing new shares.
• Employees: Impacted by the restructuring plan involving a reduction of approximately 10% in global headcount, leading to job losses and potential morale issues.
• Customers: Experienced shipment delays and elevated backlog due to ERP system implementation issues, and production inefficiencies in the sample collection product line, potentially affecting product availability and satisfaction.
• Creditors: Debt repayments have reduced outstanding obligations, but ongoing operational challenges and legal risks could still be a concern for lenders.
• Management: Faces significant challenges in integrating the 3M business, remediating internal control weaknesses, and defending against multiple lawsuits, requiring substantial time and resources.

Next Steps

• Continue to evaluate the nature and extent of economic headwinds, production inefficiencies, and market share loss and their impact on the business in fiscal year 2026.
• Implement the remediation plan to address material weaknesses in internal control over financial reporting, including enhancing control activities, developing new controls, improving documentation, expanding entity-level controls, deploying document retention protocols, providing training, and hiring qualified personnel.
• Continue efforts to improve production efficiencies for the sample collection product line for the remainder of the current fiscal year.
• Proceed with estimated capital expenditures of approximately $50 million in fiscal year 2026, with $35 million allocated to the integration of acquired 3M FSD products and the new Lansing, Michigan manufacturing facility.
• Vigorously defend against the shareholder litigation and regulatory matters.

Key Dates

Recommendation

While Neogen reported a positive net income for the six-month period, this was largely driven by a one-time gain from a divestiture and the absence of a significant goodwill impairment from the prior year. Core operational metrics show a revenue decline and a decrease in gross margin, indicating ongoing business challenges. The company is actively undergoing a significant restructuring, which carries execution risk, and continues to grapple with material weaknesses in internal controls and multiple shareholder lawsuits. These factors create considerable uncertainty. However, the company is taking steps to address these issues, including debt reduction and strategic divestitures, and has some areas of business growth. For a seasoned investor, the current situation presents a mixed bag of risks and potential for future improvement, warranting a 'hold' position to observe the effectiveness of the ongoing remediation and restructuring efforts before making a more definitive investment decision.

Keywords

Neogen, NEOG, Quarterly Report, Financial Results, Food Safety, Animal Safety, Restructuring, Divestiture, Goodwill Impairment, Internal Controls, Legal Proceedings, SEC Filing, Earnings, Performance Share Units, Stock Options, Restricted Stock Units